Ann Knoop

Research output

Research output per year 2013 2018 2020 2023 2023

• 42 Journal article
• 3 Review
• 1 Letter

Research output per year

Research output per year

Search results

• 2023

  Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study

  Hassing, C. M. S., Mejdahl, M. K., Lænkholm, A-V., Kroman, N., Knoop, A. S. & Tvedskov, T. H. F., Feb 2023, In: Breast Cancer Research and Treatment. 198, 1, p. 103-112 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • human ERBB2 protein 100%
  • Adjuvant Chemotherapy 82%
  • Estrogen Receptors 76%
  • Breast Neoplasms 52%
  • Drug Therapy 47%

• A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients

  Due, A., Berg, T., Jensen, M-B., Yammeni, S., Volmer, L., Brems-Eskildsen, A. S., Andersen, K. K., Rana, S., Knoop, A. & Kümler, I., Mar 2023, In: Acta Oncologica. 62, 2, p. 126-133 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Observational Studies 100%
  • Breast Neoplasms 82%
  • Trastuzumab 30%
  • Drug Therapy 30%
  • Progression-Free Survival 23%

• A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark

  Garly, R., Berg, T., Jensen, M-B., Knoop, A., Volmer, L., Glavicic, V., Khan, H., Poulsen, P. B., Olsen, J. & Kümler, I., Mar 2023, In: Acta Oncologica. 62, 3, p. 290-297 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • palbociclib 100%
  • Denmark 66%
  • Fulvestrant 62%
  • Aromatase Inhibitors 58%
  • Breast Neoplasms 39%

• Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world patients

  Garly, R., Knoop, A., Jensen, M-B., Berg, T., Nielsen, H. M. & Kümler, I., 23 Aug 2023, In: Danish Medical Journal. 70, 9, A01230034.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • atezolizumab 100%
  • 130-nm albumin-bound paclitaxel 97%
  • Breast Neoplasms 40%
  • Progression-Free Survival 24%
  • Survival 19%

• Identifying recurrent breast cancer patients in national health registries using machine learning

  Lauritzen, A. D., Berg, T., Jensen, M-B., Lillholm, M. & Knoop, A., Apr 2023, In: Acta Oncologica. 62, 4, p. 350-357 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Machine Learning 100%
  • Registries 70%
  • Breast Neoplasms 56%
  • Health 43%
  • Recurrence 33%
  1 Citation (Scopus)

• Real-world survival of Danish patients with HER2-positive metastatic breast cancer

  Artzi, D., Berg, T., Celik, A., Kümler, I., Kenholm, J., Al-Rawi, S., Jensen, M-B., Andersson, M. & Knoop, A., Jun 2023, In: Acta Oncologica. 62, 6, p. 601-607 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Survival 86%
  • Guidelines 38%
  • Neoplasm Metastasis 37%
  • Brain 23%
• 2022

  Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study

  Hassing, C. M. S., Mejdahl, M. K., Lænkholm, A-V., Kroman, N., Knoop, A. S. & Tvedskov, T. H. F., Nov 2022, In: Breast Cancer Research and Treatment. 196, 1, p. 197–206 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • human ERBB2 protein 100%
  • Trastuzumab 96%
  • Adjuvant Chemotherapy 82%
  • Breast 61%
  • Disease-Free Survival 32%

• First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG

  Celik, A., Berg, T., Nielsen, L. B., Jensen, M-B., Ejlertsen, B., Knoop, A. & Andersson, M., 2022, In: Breast Cancer: Basic and Clinical Research. 16, p. 1-6 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Biosimilar Pharmaceuticals 100%
  • human ERBB2 protein 88%
  • Trastuzumab 85%
  • pertuzumab 56%
  • Breast Neoplasms 45%

• Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections

  Reznitsky, F. M., Jensen, J. D., Knoop, A. & Laenkholm, A-V., Sep 2022, In: APMIS - Journal of Pathology, Microbiology and Immunology. 130, 9, p. 545-550 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Breast Neoplasms 50%
  • Neoplasms 25%
  • Tumor Microenvironment 10%
  • Pathologists 9%
• 2021

  Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study

  Pappot, H., Baeksted, C. W., Nissen, A., Knoop, A., Mitchell, S. A., Christensen, J., Hjollund, N. H. & Johansen, C., Sep 2021, In: Breast Cancer: Basic and Clinical Research. 28, 5, p. 1096-1099 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Patient Reported Outcome Measures 100%
  • Breast Neoplasms 57%
  • Social Adjustment 43%
  • Population 35%
  • Febrile Neutropenia 28%

• Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

  Ehmsen, S., Jakobsen, L. H., Lendorf, M. E., Eefsen, R. L., Bentsen, L., Knoop, A. S., Aggerholm-Pedersen, N., Skuladottir, H., Herrstedt, J., Jensen, L. H., Rotbøl, C., Damm, M. B., Wedervang, K., Glenthøj, A., Ryg, J., Frederiksen, H. & Kodahl, A. R., Jul 2021, In: Acta Oncologica. 60, 7, p. 859-865 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • SARS Virus 100%
  • Cohort Studies 46%
  • Infections 32%
  • Neoplasms 21%
  • Comorbidity 18%
• 2020

  Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients

  Christensen, T., Berg, T., Nielsen, L. B., Andersson, M., Jensen, M-B. & Knoop, A., Jun 2020, In: Breast. 51, p. 34-39 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Observational Studies 100%
  • Breast Neoplasms 82%
  • Progression-Free Survival 64%
  • Population 50%
  • Survival 39%

• Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

  Skriver, S. K., Jensen, M-B., Eriksen, J-O., Ahlborn, L. B., Knoop, A. S., Rossing, M., Ejlertsen, B. & Laenkholm, A-V., Nov 2020, In: Breast Cancer Research and Treatment. 184, 1, p. 123-133 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Letrozole 100%
  • Breast Neoplasms 46%
  • Mutation 27%
  • Exons 20%
  • Survival 13%
  2 Citations (Scopus)

• Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

  Christensen, T. D., Buhl, A. S. K., Christensen, I. J., Buhl, I. K., Balslev, E., Knoop, A. S., Danø, H., Glavicic, V., Luczak, A., Langkjer, S. T., Linnet, S., Jakobsen, E. H., Bogovic, J., Ejlertsen, B., Rasmussen, A., Hansen, A., Knudsen, S., Jensen, P. B. & Nielsen, D., Mar 2020, In: Breast Cancer: Basic and Clinical Research. 27, 2, p. 266-276 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Fulvestrant 100%
  • Breast Neoplasms 47%
  • Pharmaceutical Preparations 23%
  • Biopsy 22%
  • Therapeutics 10%
  1 Citation (Scopus)

• Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology

  Mejdahl, M. K., Wohlfahrt, J., Holm, M., Knoop, A. S., Tjønneland, A., Melbye, M., Kroman, N. & Balslev, E., Jul 2020, In: Breast Cancer Research and Treatment. 182, 1, p. 229-238 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Unilateral Breast Neoplasms 100%
  • Breast Neoplasms 66%
  • Lobular Carcinoma 38%
  • Neoplasms 12%
  • Denmark 10%
  5 Citations (Scopus)

• Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

  Skriver, S. K., Jensen, M-B., Knoop, A. S., Ejlertsen, B. & Laenkholm, A-V., 14 May 2020, In: Breast Cancer Research. 22, 1, p. 46 46.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Letrozole 100%
  • Tumor-Infiltrating Lymphocytes 91%
  • Estrogen Receptors 67%
  • Breast Neoplasms 46%
  • Residual Neoplasm 17%
  19 Citations (Scopus)
• 2019

  Breast cancer mortality in synchronous bilateral breast cancer patients

  Mejdahl, M. K., Wohlfahrt, J., Holm, M., Balslev, E., Knoop, A. S., Tjønneland, A., Melbye, M. & Kroman, N., Apr 2019, In: British Journal of Cancer. 120, 7, p. 761-767 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Unilateral Breast Neoplasms 100%
  • Breast Neoplasms 94%
  • Mortality 74%
  • Neoplasms 26%
  • Cohort Studies 11%

• Handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy in a cluster randomized trial with electronic patient-reported outcomes as intervention

  Baeksted, C. W., Nissen, A., Knoop, A., Christiansen, M. & Pappot, H., Nov 2019, In: Breast. 25, 6, p. 1295-1296 2 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

• Patients' experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy

  Bæksted, C. W., Nissen, A., Knoop, A. S. & Pappot, H., 2019, In: Research Involvement and Engagement. 5, p. 36

  Research output: Contribution to journal › Journal article › Research › peer-review

  • adverse events 100%
  • Adjuvant Chemotherapy 75%
  • cancer 67%
  • Communication 55%
  • Breast Neoplasms 47%

• Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)

  Pappot, H., Baeksted, C., Knoop, A., Mitchell, S. A., Nissen, A. & Johansen, C., 2019, In: Breast. 25, 2, p. 269-272

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Patient Reported Outcome Measures 100%
  • Terminology 91%
  • Organizations 75%
  • Breast Neoplasms 57%
  • Febrile Neutropenia 37%
  9 Citations (Scopus)
• 2018

  Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer

  Kodahl, A. R., Ehmsen, S., Pallisgaard, N., Jylling, A. M. B., Jensen, J. D., Laenkholm, A-V., Knoop, A. S. & Ditzel, H. J., Jun 2018, In: Molecular Oncology. 12, 6, p. 925-935 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Circulating Tumor DNA 100%
  • Breast Neoplasms 44%
  • Mutation 34%
  • Serum 23%
  • Liquid Biopsy 12%
  56 Citations (Scopus)

• Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

  Olsen, J., Jensen, K. F., Olesen, D. S. & Knoop, A., 2018, In: Journal of Comparative Neurology. 7, 5, p. 411-419

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Trastuzumab 100%
  • Intravenous Administration 79%
  • Breast Neoplasms 53%
  • Costs and Cost Analysis 52%
  • Salaries and Fringe Benefits 25%
  12 Citations (Scopus)

• Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

  Ejlertsen, B., Offersen, B. V., Overgaard, J., Christiansen, P., Jensen, M-B., Kroman, N., Knoop, A. S. & Mouridsen, H., 2018, In: Acta oncologica . 57, 1, p. 3-12

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Taxoids 15%
  • Aromatase Inhibitors 14%
  • human ERBB2 protein 14%
  • Information Dissemination 14%
  13 Citations (Scopus)

• Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression

  Krøigård, A. B., Larsen, M. J., Lænkholm, A-V., Knoop, A. S., Jensen, J. D., Bak, M., Mollenhauer, J., Thomassen, M. & Kruse, T. A., 2018, In: PLoS One. 13, 1, p. e0189887

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Neoplasm Metastasis 96%
  • Genes 63%
  • Silent Mutation 36%
  • Adherens Junctions 33%
  21 Citations (Scopus)

• Molecular subtyping of breast cancer improves identification of both high and low risk patients

  Rossing, M., Østrup, O., Majewski, W. W., Kinalis, S., Jensen, M-B., Knoop, A., Kroman, N., Talman, M-L., Hansen, T. V. O., Ejlertsen, B. & Nielsen, F. C., 2018, In: Acta oncologica . 57, 1, p. 58-66

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Immunohistochemistry 65%
  • Gene Expression Profiling 64%
  • Adjuvant Chemotherapy 63%
  • Transcriptome 57%
  9 Citations (Scopus)

• Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

  Jensen, M-B., Nielsen, T. O., Knoop, A. S., Laenkholm, A-V., Balslev, E. & Ejlertsen, B., 2018, In: Acta oncologica . 57, 1, p. 135-140

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Recurrence 89%
  • Mortality 78%
  • Statistical Models 35%
  • Neoplasms 30%
  5 Citations (Scopus)

• Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)

  Skriver, S. K., Laenkholm, A-V., Rasmussen, B. B., Handler, J., Grundtmann, B., Tvedskov, T. F., Christiansen, P., Knoop, A. S., Jensen, M-B. & Ejlertsen, B., 2018, In: Acta oncologica . 57, 1, p. 31-37

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Letrozole 100%
  • Estrogen Receptors 67%
  • Breast Neoplasms 46%
  • Neoadjuvant Therapy 37%
  • Aromatase Inhibitors 9%
  9 Citations (Scopus)

• Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer

  Rosvig, L. H., Langkjer, S. T., Knoop, A. & Jensen, A. B., 2018, In: Acta oncologica . 57, 1, p. 156-159

  Research output: Contribution to journal › Journal article › Research › peer-review

  2 Citations (Scopus)

• PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

  Lænkholm, A-V., Jensen, M-B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., Ferree, S., Schaper, C., Nielsen, T. O., Haffner, T., Kibøl, T., Talman, M-L., Bak Jylling, A. M., Tabor, T. P. & Ejlertsen, B., 2018, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36, 8, p. 735-740

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Hormones 100%
  • Breast Neoplasms 90%
  • Recurrence 81%
  • Confidence Intervals 33%
  • Therapeutics 23%
  91 Citations (Scopus)

• Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

  Buhl, A. S. K., Christensen, T. D., Christensen, I. J., Nelausen, K. M., Balslev, E., Knoop, A. S., Brix, E. H., Svensson, E., Glavicic, V., Luczak, A., Langkjer, S. T., Linnet, S., Jakobsen, E. H., Bogovic, J., Ejlertsen, B., Rasmussen, A., Hansen, A., Knudsen, S., Nielsen, D. & Jensen, P. B., 2018, In: Breast Cancer Research and Treatment. 172, 2, p. 391-400

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Epirubicin 100%
  • Breast Neoplasms 50%
  • Prospective Studies 50%
  • Pharmaceutical Preparations 32%
  • Messenger RNA 10%
  5 Citations (Scopus)
• 2017

  Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

  Ejlertsen, B., Tuxen, M. K., Jakobsen, E. H., Jensen, M-B., Knoop, A. S., Højris, I., Ewertz, M., Balslev, E., Danø, H., Vestlev, P. M., Kenholm, J., Nielsen, D. L., Bechmann, T., Andersson, M., Cold, S., Nielsen, H. M., Maae, E., Carlsen, D. & Mouridsen, H. T., Aug 2017, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35, 23, p. 2639-2646

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Epirubicin 100%
  • Docetaxel 88%
  • Disease-Free Survival 74%
  • Cyclophosphamide 73%
  • Breast Neoplasms 50%
  41 Citations (Scopus)

• Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence

  Krøigård, A. B., Larsen, M. J., Brasch-Andersen, C., Lænkholm, A-V., Knoop, A. S., Jensen, J. D., Bak, M., Mollenhauer, J., Thomassen, M. & Kruse, T. A., 9 Mar 2017, In: Scientific Reports. 7, p. e43813

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Neoplasm Metastasis 96%
  • Neoplasms 40%
  • Whole Exome Sequencing 37%
  • High-Throughput Nucleotide Sequencing 30%
  20 Citations (Scopus)

• Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial

  Gligorov, J., Curigliano, G., Müller, V., Knoop, A., Jenkins, V., Verma, S., Osborne, S., Lauer, S., Machackova, Z., Fallowfield, L. & Pivot, X., Aug 2017, In: Breast . 34, p. 89-95 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Trastuzumab 100%
  • Safety 49%
  • Injection Site Reaction 38%
  • Sudden Infant Death 34%
  • Syringes 31%
  15 Citations (Scopus)
• 2016

  A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

  De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D. & Knoop, A., Mar 2016, In: Cancer Medicine. 5, 3, p. 389-97 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Time and Motion Studies 100%
  • Trastuzumab 99%
  • Sudden Infant Death 64%
  • Breast Neoplasms 53%
  • Delivery of Health Care 31%
  68 Citations (Scopus)

• Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

  Kümler, I., Knoop, A. S., Jessing, C. A. R., Ejlertsen, B. & Nielsen, D. L., 2016, In: ESMO Open. 1, 4, p. e000062

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Fulvestrant 100%
  • Aromatase Inhibitors 92%
  • Hormones 52%
  • Letrozole 51%
  • Breast Neoplasms 47%
  40 Citations (Scopus)
• 2015

  Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis

  Krøigård, A. B., Larsen, M. J., Lænkholm, A-V., Knoop, A. S., Jensen, J. D., Bak, M., Mollenhauer, J., Kruse, T. A. & Thomassen, M., 20 Mar 2015, In: Oncotarget. 6, 8, p. 5634-49 16 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Genome 100%
  • Breast Neoplasms 93%
  • Neoplasm Metastasis 90%
  • Neoplasms 47%
  • Exome 29%
  38 Citations (Scopus)

• Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer

  Eckhoff, L., Feddersen, S., Knoop, A. S., Ewertz, M. & Bergmann, T. K., Apr 2015, In: Acta oncologica . 54, 4, p. 530-7 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Pharmacogenetics 100%
  • Docetaxel 98%
  • Peripheral Nervous System Diseases 72%
  • Case-Control Studies 70%
  • Breast Neoplasms 56%
  39 Citations (Scopus)

• Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

  Thomsen, K., Lyng, M. B., Elias, D., Vever, H., Knoop, A. S., Lykkesfeldt, A. E., Lænkholm, A-V. & Ditzel, H. J., Dec 2015, In: Breast Cancer Research and Treatment. 154, 3, p. 483-94 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Aromatase Inhibitors 100%
  • Breast Neoplasms 51%
  • Gene Expression 48%
  • exemestane 45%
  • Growth 30%
  8 Citations (Scopus)
• 2014

  Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

  Knoop, A. S., Lænkholm, A-V., Jensen, M-B., Nielsen, K. V., Andersen, J., Nielsen, D., Ejlertsen, B. & Danish Breast Cancer Cooperative Group, May 2014, In: European journal of cancer (Oxford, England : 1990). 50, 8, p. 1412-21 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tamoxifen 100%
  • Progesterone Receptors 99%
  • Estrogen Receptors 88%
  • Breast Neoplasms 60%
  • Recurrence 14%
  21 Citations (Scopus)
• 2013

  Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

  Bjerre, C. A., Knoop, A., Bjerre, K., Larsen, M. S., Henriksen, K. L., Lyng, M. B., Ditzel, H. J., Rasmussen, B. B., Brünner, N. A., Ejlertsen, B. & Laenkholm, A-V., Jan 2013, In: Acta oncologica . 52, 1, p. 82-90 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tissue Inhibitor of Metalloproteinase-1 100%
  • Estrogen Receptors 78%
  • Breast Neoplasms 53%
  • human ERBB2 protein 51%
  • Tamoxifen 44%
  12 Citations (Scopus)

• Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

  Lyng, M. B., Lænkholm, A-V., Tan, Q., Vach, W., Gravgaard, K. H., Knoop, A. & Ditzel, H. J., 2013, In: P L o S One. 8, 1, p. e54078

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tamoxifen 100%
  • Estrogen Receptors 88%
  • Transcriptome 86%
  • Breast Neoplasms 60%
  • Recurrence 26%
  12 Citations (Scopus)

• Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

  Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L. & PrefHer Study Group, Sep 2013, In: The Lancet Oncology. 14, 10, p. 962-70 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Trastuzumab 100%
  • Intravenous Administration 79%
  • Breast Neoplasms 53%
  • Patient Preference 31%
  • Pharmacokinetics 21%
  170 Citations (Scopus)